Navigation Links
Factor in Medical Technology

Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease

... that the carriers of a common genetic risk factor for Alzheimer's disease begin to have memory ... of the APOE e4 gene, the major genetic risk factor for developing Alzheimer's disease at older ages. ... they are accelerated by the major genetic risk factor for Alzheimer's disease," said Eric Reiman, M.D., ...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... with edoxaban(2) - an investigational oral factor Xa inhibitor - provides insights into why ... is an oral anticoagulant that directly inhibits factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

... --Orally Active Enhancer of Human Nerve Growth factor Has Demonstrated Promising Activity ... agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l ... (CIPN) later this year. "Nerve growth factor has long been of interest as a potential therapy ...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) Lead ... Leukine(R) (sargramostim) is the only growth factor approved in the U.S. for use following induction ... indications, Leukine is the only myeloid growth factor approved to reduce the incidence of infections ...

Senesco Announces H1N1 Influenza Survival Test Results in Mice

... Mice treated with an siRNA against Senesco's factor 5A gene had a 52% survival rate as opposed to a ... mice) were administered Senesco's siRNA against factor 5A approximately 24 hours after infection and ... "These prototype studies have demonstrated that factor 5A is a promising candidate for future study in ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... cancer (NSCLC) patients who have epidermal growth factor receptor (EGFR) mutations.(2) "Lung cancer ... dual inhibitor of the epidermal growth factor receptor (EGFR) and human epithelial receptor 2 ... inhibiting vascular endothelial growth factor receptors (VEGFRs), platelet-derived ...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

... of kidney disease, as well as an important risk factor of cardiovascular disease (CVD).(1) The secondary ... dysfunction, and is a strong independent risk factor for cardiovascular disease.(5) Hypertension, or high blood pressure, is a major factor for the development and acceleration of kidney ...

Isis and Collaborators Present New Research at the ATVB Annual Conference

... and a second on an antisense inhibitor to factor XI, which has the potential to create a drug to ... "Antisense oligonucleotide-mediated depletion of factor XI results in effective anticoagulation with a ... demonstrating that antisense drugs that inhibit factor XI can prevent thrombus formation in models of ...

Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments

... in several genes including complement factor H (CFH), complement factor B (CFB), complement factor 2 (C2) and ...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

... that are mediated by vascular endothelial growth factor (VEGF), we are hopeful that VEGF Trap-Eye may ... VEGF Trap-Eye Vascular Endothelial Growth factor (VEGF) is a naturally occurring protein in the ... of VEGF-A along with the related Placental Growth factor (PlGF). Investigational VEGF Trap-Eye is a ...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

... a portfolio of innovative DNA-based growth factor therapeutics for cardiovascular and related ... (TRC) is focused on the development of growth factor therapeutics for the treatment of severe chronic ... tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic designed for potential application by ...

Study Finds Family History, Higher Incidence of Sunburns Associated With Rosacea

... a broad-spectrum sunscreen with a Sun Protection factor (SPF) of 15 or higher and to practice other ... not be determined if sunburns were a contributing factor to rosacea or if patients with rosacea were more ... excess weight could be found to be a contributing factor to the condition," said Dr. Kimball. Dr. ...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

... population, where age is the major risk factor for "shoulder girdle" problems such as rotator ... and soft tissue health are now surfacing. Growth factor combinations such as bone morphogenetic protein, platelet rich plasma, and platelet derived growth factor and other potential therapeutic agents are now ...

Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B

... IB1001, an Intravenous Recombinant factor IX (rFIX) Product for the Treatment of Hemophilia ... trial of IB1001, an intravenous (IV) recombinant factor IX (rFIX) product for control and prevention of ... the past two decades. We continue to develop a factor product portfolio in both IV and non-invasive ...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

... by targeting vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1-3). It is also under ... kinases, including platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-kit), two proteins involved in cell ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... that belong to a new class of therapies called factor Xa inhibitors. These studies evaluated the ... idrabiotaparinux, an anticoagulant and indirect factor Xa inhibitor that links idraparinux to biotin, ... egg protein that binds with biotin to reverse the factor Xa inhibiting activity of idrabiotaparinux. At ...

New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation

... dose of DU-176b, an investigational oral factor Xa inhibitor, experienced comparable safety and ... a Phase II clinical study evaluating an oral factor Xa inhibitor in atrial fibrillation patients. ... is an oral anticoagulant that directly inhibits factor Xa, ...

Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation

... III trial for DU-176b, an investigational oral factor Xa inhibitor, in patients with atrial ... III global study, Effective Anticoagulation with factor Xa Next Generation in Atrial Fibrillation ... is an oral anticoagulant that directly inhibits factor Xa, ...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

... About Leukine Leukine is a growth factor that helps fight infection and disease in ... Pharmaceuticals. Leukine is the only growth factor approved in the U.S. for use following induction ... indications, Leukine is the only myeloid growth factor approved to reduce the incidence of infections ...

Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483

... company's novel, first-in-class small-molecule factor VIIa inhibitor. The trial was conducted in ... available anticoagulants. The Factor VIIa: tissue factor complex, the pharmacologic target of PCI-27483, ... in many malignancies. Up-regulation of tissue factor expression is observed in pancreatic, lung, ...

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

... by targeting vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1-3). It is also under ... kinases, including platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-kit), two proteins involved in cell ...

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

... entitled "RNAi-Mediated Silencing of Nuclear factor Erythroid-2-Related factor 2 Gene Expression in Non-Small Cell Lung Cancer ... reduction of Nuclear Factor Erythroid-2-Related factor 2 (Nrf2) expression in vitro and in in vivo mouse ...

FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A

... approval provides these patients with the only factor VIII treatment that the FDA has determined safe ... "The FDA approval of Kogenate FS as the first factor VIII treatment product in the U.S. to be used to replenish factor VIII levels in a prophylactic manner marks a ...

KGI Professor Ian Phillips Awarded Defense Grants for Medical Combat Research

... on" a gene to produce a blood clotting protein, factor VII. When a blood vessel is broken, the ... Low oxygen would activate the Hemostat causing factor VII to be made in the injured tissue. factor VII seals broken blood vessels, and as oxygen ...

Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b

... Cardiology showed that the investigational oral factor Xa inhibitor DU-176b reduced the incidence of ... and we look forward to further study on this factor Xa inhibitor," said Gary Raskob, Ph.D., Dean, ... "As the company that discovered one of the first factor Xa small molecules (DX-9065a), we are proud to be ...

Portola Completes $60 Million Financing to Advance Its Therapeutic Programs

... pre-clinical pipeline including its novel factor Xa inhibitor antidote, which has the potential to ... funds will also help us advance a novel factor Xa inhibitor antidote and our Syk and JAK ... 2 drug candidate, is an oral Factor Xa inhibitor. factor Xa is a validated target for which there ...

Senesco Chooses VGXI to Produce Factor 5A Plasmid

... Company's combination therapy consisting of the factor 5A gene and siRNA against factor 5A. Senesco has previously reported positive ... tumors in immunodeficient mice. The factor 5A plasmid being produced by VGXI, as Senesco's ...

Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System

... that RB006 effectively inhibited the activity of factor IXa, a protein essential to blood clotting and ... Study of Antidote-Controlled Modulation of factor IXa Activity in Patients with Stable Coronary ... selectively and potently binds to and inhibits factor IXa, a protein that is critical to blood ...

Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress

... 1988 in Bonn, Germany. This advent of recombinant factor VIII technology represented a leap forward in the ... the only company with a long-acting recombinant factor VIII protein in human clinical trials. We are ... Kogenate(R) FS Kogenate(R) FS (Antihemophilic factor [Recombinant]) is a recombinant factor VIII ...

Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia

... second-generation variant of human coagulation factor VIIa, as a development candidate for the ... in potency compared with the marketed recombinant factor VIIa product, NovoSeven(R) and a competing, ... patients in 2009. "Patients receiving factor VIIa therapy typically require multiple doses of ...

Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer

... of PCI-27483, the company's small-molecule factor VIIa inhibitor. The data were presented during ... for Pharmacyclics. "These findings indicate that factor VIIa inhibition is potentially a novel treatment approach for patients whose tumors depend on factor VIIa activity for progression." ...

Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS

... signaling by locking epidermal growth factor receptor (EGFr) molecules into a very compact, ... (zalutumumab) locks epidermal growth factor receptor (EGFr) molecules into a very compact, ... defense activity known as ADCC, block growth factor binding to EGF receptors, and we now ...

Baxter Announces Recombinant Factor IX Development Program For Hemophilia B

... pre-clinical programs to develop recombinant factor IX proteins to treat hemophilia B. Baxter will develop both an unmodified recombinant factor IX therapy for treatment of acute bleeding ... modified, long-acting version of recombinant factor IX therapy for prophylaxis of bleeding ...

CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity

... the first time it is feasible to genetically fuse factor VIIa (FVIIa) to human albumin, prolonging ... comparable to wild type rFVIIa. Recombinant factor VIIa (rFVIIa) may be used to control ... response that inhibits the substituted clotting factor from stopping a bleeding episode. However, rFVIIa ...

Senesco Technologies Initiates Preclinical Studies for Cancer Target

... will further test the ability of Senesco's factor 5A gene technology to up-regulate apoptosis of ... evaluate delivery molecules for encapsulation of factor 5A to enhance the time the gene will circulate ... experiments, together with the results of other factor 5A studies, will be reviewed to determine ...

New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer

... The study enrolled patients with epidermal growth factor receptor (EGFR)- expressing metastatic colorectal ... and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays ... metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can ...

Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B

... trials with IB1001, an intravenous recombinant factor IX (rFIX) product for the on demand and ... IB1001, compared with the commercially available factor IX products; rFIX, BeneFix(R) and plasma-derived ... compared to the clinically proven commercial factor IX products. Our cost-effective manufacturing ...

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

... such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. These data are from post-hoc ... these two factors. Change in mean score on factor 1 (socio-emotional role independence) was 0.921 ... than 0.0001). Change in mean score on factor 2 (physical independence) was 0.499 for the ...

Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions

... Evaluation Anticoagulant Inhibits Clotting factor IXa; Matched Antidote Rapidly Reverses ... showed RB006 completely inhibited the activity of factor IXa, a protein essential to blood clotting, and ... 1 mg/kg dose of RB006 resulted in 100 percent factor IXa inhibition. The studies also demonstrated an ...

New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions

... of research on childhood obesity as a risk factor for heart disease in later life provide another ... Scientific Sessions, found that the new risk factor -- called BMI rebound age -- indicates that the ... elevated left ventricular mass, a known risk factor for heart attack. And, a study presented at ...
Other Contents
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
(Date:12/22/2014)... Naples, Florida (PRWEB) December 22, 2014 ... this holiday season, the gift of health and vitality. ... is offering its three top-selling anti-aging formulas in special ... with free rush delivery. , Each bottle contains ... digestion, areas that don't work as well as we ...
(Date:12/22/2014)... 2014 Xarelto Lawsuit News : ... judges has granted a request to centralize pending and ... Court, Eastern District of Louisiana. The U.S. Judicial Panel ... 12 to transfer over 50 Xarelto cases–21 lawsuits and ... Louisiana court for consolidation under U.S. District Judge Eldon ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... Recently, BambooFlooringChina.com, a famous bamboo lumber supplier, has ... and launched a bamboo flooring promotion with great discounts, ... 30, 2015. , According to the CEO of the ... available today; it has a highly distinctive grain with ... woven bamboo is made by a unique manufacturing process ...
Breaking Medicine News(10 mins):Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
Other TagsOther Tags